Thrombolytic therapy for stroke in patients with preexisting cognitive impairment. Murao, K., Leys, D., Jacquin, A., Kitazono, T., Bordet, R., Béjot, Y., Kimura, K., Godefroy, O., Wakisaka, Y., Moulin, S., Ago, T., Sibon, I., Bombois, S., Mas, J., Hénon, H., Pasquier, F., Giroud, M., Cordonnier, C., Okada, Y., & OPHELIE-COG investigators Neurology, 82(23):2048–2054, June, 2014.
doi  abstract   bibtex   
OBJECTIVE: We aimed to evaluate the influence of prestroke cognitive impairment (PSCI) on outcomes in stroke patients treated with IV recombinant tissue plasminogen activator (rtPA). METHODS: OPHELIE-COG was a prospective observational multicenter study conducted in French and Japanese patients treated with IV rtPA for cerebral ischemia. The preexisting cognitive status was evaluated by the short version of the Informant Questionnaire on Cognitive Decline in the Elderly. PSCI was defined as a mean score \textgreater3. The primary endpoint was a favorable outcome (modified Rankin Scale [mRS] score 0-1) after 3 months. Secondary endpoints were symptomatic intracerebral hemorrhage (sICH), mRS scores 0-2, and mortality at 3 months. We performed a pooled analysis with Biostroke and Strokdem. RESULTS: Of 205 patients, 62 (30.2%) met criteria for PSCI. They were 11 years older (p \textless 0.001). Although they had more sICH and were less frequently independent after 3 months, they did not differ for any endpoint after adjustment for age, baseline NIH Stroke Scale score, and onset-to-needle time: sICH (odds ratio [OR] 2.78; 95% confidence interval [CI] 0.65-11.86), mRS 0-1 (OR 0.82; 95% CI 0.41-1.65), mRS 0-2 (OR 0.62; 95% CI 0.28-1.37), death (OR 0.40; 95% CI 0.08-2.03). The pooled analysis found no association of PSCI with any endpoint. CONCLUSIONS: Ischemic stroke patients with PSCI should receive rtPA if they are eligible. This conclusion cannot be extended to severe cognitive impairment or severe strokes. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with PSCI presenting with acute ischemic stroke, IV rtPA improves outcomes.
@article{murao_thrombolytic_2014,
	title = {Thrombolytic therapy for stroke in patients with preexisting cognitive impairment},
	volume = {82},
	issn = {1526-632X},
	doi = {10.1212/WNL.0000000000000493},
	abstract = {OBJECTIVE: We aimed to evaluate the influence of prestroke cognitive impairment (PSCI) on outcomes in stroke patients treated with IV recombinant tissue plasminogen activator (rtPA).
METHODS: OPHELIE-COG was a prospective observational multicenter study conducted in French and Japanese patients treated with IV rtPA for cerebral ischemia. The preexisting cognitive status was evaluated by the short version of the Informant Questionnaire on Cognitive Decline in the Elderly. PSCI was defined as a mean score {\textgreater}3. The primary endpoint was a favorable outcome (modified Rankin Scale [mRS] score 0-1) after 3 months. Secondary endpoints were symptomatic intracerebral hemorrhage (sICH), mRS scores 0-2, and mortality at 3 months. We performed a pooled analysis with Biostroke and Strokdem.
RESULTS: Of 205 patients, 62 (30.2\%) met criteria for PSCI. They were 11 years older (p {\textless} 0.001). Although they had more sICH and were less frequently independent after 3 months, they did not differ for any endpoint after adjustment for age, baseline NIH Stroke Scale score, and onset-to-needle time: sICH (odds ratio [OR] 2.78; 95\% confidence interval [CI] 0.65-11.86), mRS 0-1 (OR 0.82; 95\% CI 0.41-1.65), mRS 0-2 (OR 0.62; 95\% CI 0.28-1.37), death (OR 0.40; 95\% CI 0.08-2.03). The pooled analysis found no association of PSCI with any endpoint.
CONCLUSIONS: Ischemic stroke patients with PSCI should receive rtPA if they are eligible. This conclusion cannot be extended to severe cognitive impairment or severe strokes.
CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with PSCI presenting with acute ischemic stroke, IV rtPA improves outcomes.},
	language = {eng},
	number = {23},
	journal = {Neurology},
	author = {Murao, Kei and Leys, Didier and Jacquin, Agnès and Kitazono, Takanari and Bordet, Régis and Béjot, Yannick and Kimura, Kazumi and Godefroy, Olivier and Wakisaka, Yoshinobu and Moulin, Solène and Ago, Tetsuro and Sibon, Igor and Bombois, Stéphanie and Mas, Jean-Louis and Hénon, Hilde and Pasquier, Florence and Giroud, Maurice and Cordonnier, Charlotte and Okada, Yasushi and {OPHELIE-COG investigators}},
	month = jun,
	year = {2014},
	pmid = {24827495},
	keywords = {Aged, Humans, Cognition Disorders, Female, Male, Middle Aged, Prospective Studies, Aged, 80 and over, Cerebral Hemorrhage, Treatment Outcome, Stroke, Brain Ischemia, Fibrinolytic Agents, Thrombolytic Therapy, Tissue Plasminogen Activator},
	pages = {2048--2054}
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021